These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16114988)

  • 1. Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses.
    Shi M; Hao S; Su L; Zhang X; Yuan J; Guo X; Zheng C; Xiang J
    Cancer Biother Radiopharm; 2005 Aug; 20(4):401-9. PubMed ID: 16114988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor.
    Cairns CM; Gordon JR; Li F; Baca-Estrada ME; Moyana T; Xiang J
    J Immunol; 2001 Jul; 167(1):57-65. PubMed ID: 11418632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor.
    Shi M; Su L; Hao S; Guo X; Xiang J
    Tumori; 2005; 91(6):531-8. PubMed ID: 16457153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
    Liu Y; Qureshi M; Xiang J
    Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors.
    Liu Y; Huang H; Saxena A; Xiang J
    Cancer Gene Ther; 2002 Jun; 9(6):533-42. PubMed ID: 12032664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity.
    Liu Y; Zhang W; Chan T; Saxena A; Xiang J
    Leuk Res; 2002 Aug; 26(8):757-63. PubMed ID: 12191571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.
    Ramarathinam L; Castle M; Wu Y; Liu Y
    J Exp Med; 1994 Apr; 179(4):1205-14. PubMed ID: 7511683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
    Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
    Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
    Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
    Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fibroblast growth factor 2 on stromal cell-derived factor 1 production by bone marrow stromal cells and hematopoiesis.
    Nakayama T; Mutsuga N; Tosato G
    J Natl Cancer Inst; 2007 Feb; 99(3):223-35. PubMed ID: 17284717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses.
    Dunussi-Joannopoulos K; Zuberek K; Runyon K; Hawley RG; Wong A; Erickson J; Herrmann S; Leonard JP
    Blood; 2002 Sep; 100(5):1551-8. PubMed ID: 12176869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells.
    Xiang J; Chen Z; Huang H; Moyana T
    Leuk Res; 2001 Oct; 25(10):909-15. PubMed ID: 11532525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.
    Biragyn A; Tani K; Grimm MC; Weeks S; Kwak LW
    Nat Biotechnol; 1999 Mar; 17(3):253-8. PubMed ID: 10096292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
    Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
    J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
    Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.